Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Liabilities (2022 - 2025)

Stoke Therapeutics has reported Total Liabilities over the past 4 years, most recently at $66.0 million for Q4 2025.

  • Quarterly results put Total Liabilities at $66.0 million for Q4 2025, up 55.12% from a year ago — trailing twelve months through Dec 2025 was $66.0 million (up 55.12% YoY), and the annual figure for FY2025 was $66.0 million, up 55.12%.
  • Total Liabilities for Q4 2025 was $66.0 million at Stoke Therapeutics, up from $52.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for STOK hit a ceiling of $77.1 million in Q2 2022 and a floor of $42.5 million in Q4 2024.
  • Median Total Liabilities over the past 4 years was $66.4 million (2023), compared with a mean of $64.1 million.
  • Biggest five-year swings in Total Liabilities: crashed 38.16% in 2024 and later surged 55.12% in 2025.
  • Stoke Therapeutics' Total Liabilities stood at $71.2 million in 2022, then fell by 3.43% to $68.8 million in 2023, then tumbled by 38.16% to $42.5 million in 2024, then surged by 55.12% to $66.0 million in 2025.
  • The last three reported values for Total Liabilities were $66.0 million (Q4 2025), $52.2 million (Q3 2025), and $49.6 million (Q2 2025) per Business Quant data.